The best of EcoWatch, right in your inbox. Sign up for our email newsletter!
First Glyphosate Trial, of Thousands, Begins as Plaintiff Fights for His Life
Monsanto may have dropped its name, but it can't drop the thousands of cases being brought against it by cancer sufferers claiming its weed-killer Roundup gave them non-Hodgkin's lymphoma, the first of which goes to trial Monday, CNN reported.
The first plaintiff to get his day in court is Dewayne Johnson, a 46-year-old Bay-area father of two, but for Johnson that is a dubious honor. Johnson is being granted an expedited trial because his doctors say he is nearing death, and California law facilitates speedier trials in such cases.
Johnson worked doing pest management for a county school system and used Roundup 20 to 30 times per year in the line of duty. Now, he has days when lesions cover 80 percent of his body and he is too ill to speak.
"Mr. Johnson is angry and is the most safety-oriented person I know," his attorney Timothy Litzenburg told CNN. "Right now, he is the bravest dude in America. Whatever happens with the trial and his health, his sons get to know that."
Litzenburg also represents "more than 2,000 non-Hodgkin's lymphoma sufferers who used Roundup extensively," he told CNN.
The trial will hinge on whether Roundup's key ingredient glyphosate causes cancer and whether Monsanto failed to adequately warn customers.
Monsanto, for its part, has long insisted on glyphosate's safety.
"More than 800 scientific studies, the U.S. Environmental Protection Agency (EPA), the National Institutes of Health and regulators around the world have concluded that glyphosate is safe for use and does not cause cancer," Scott Partridge, Monsanto's vice president of strategy, said in a statement reported by CNN.
But the World Health Organization's International Agency for Research on Cancer (IARC) ruled in 2015 that glyphosate was "probably carcinogenic to humans" based on studies of exposure in the agricultural sector published in the U.S., Canada and Sweden since 2001 and on laboratory experiments conducted on animals.
In March, a San Francisco judge unsealed documents casting doubt on the legitimacy of the studies finding glyphosate safe. The documents revealed Monsanto employees had ghostwritten glyphosate research for academics to sign and that a senior EPA official had killed a glyphosate review after speaking with Monsanto.Johnson's trial will begin nearly a week after another California judge ruled that the state could not require cancer-risk labels on products containing glyphosate, saying evidence was inconclusive, AgriPulse reported. The new labels were scheduled to be required in July, but the judge's ruling has delayed their roll-out, though it is not the final ruling in the case.
EcoWatch Daily Newsletter
By John R. Platt
Both eyes open. Look for potential threats coming from all sides. Be prepared to change course at a moment's notice.
By Nick Cunningham
A growing number of refineries around the world are either curtailing operations or shutting down entirely as the oil market collapses.
The Trump administration is expected to unveil its final replacement of Obama-era fuel-efficiency standards for cars and light trucks Tuesday in a move likely to pump nearly a billion more tons of carbon dioxide into the atmosphere over the lifetime of those less-efficient vehicles.
By Jake Johnson
Just over a month after proclaiming that the number of coronavirus cases in the U.S. would soon "be down to close to zero," President Donald Trump said during a press briefing on the White House lawn Sunday that limiting U.S. deaths from the pandemic to between 100,000 and 200,000 people would mean his administration and the country as a whole did "a very good job."
Documents unearthed in a lawsuit brought by a Missouri farmer who claimed that Monsanto and German chemical maker BASF's dicamba herbicide ruined his peach orchard revealed that the two companies knew their new agricultural seed and chemical system would likely damage many U.S. farms, according to documents seen by The Guardian.